ZNTL - Zentalis Pharmaceuticals, Inc.

1.04
-0.120   -11.538%

Share volume: 896,937
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$1.16
-0.12
-0.10%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
19%
Profitability 0%
Dept financing 31%
Liquidity 50%
Performance 27%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-11.11%
1 Month
-41.90%
3 Months
-62.18%
6 Months
-65.45%
1 Year
-93.39%
2 Year
-94.03%
Key data
Stock price
$1.04
P/E Ratio 
0.00
DAY RANGE
$1.02 - $1.23
EPS 
-$1.77
52 WEEK RANGE
$1.02 - $14.50
52 WEEK CHANGE
-$92.94
MARKET CAP 
215.934 M
YIELD 
N/A
SHARES OUTSTANDING 
71.108 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-06-2025
BETA 
1.76
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$928,382
AVERAGE 30 VOLUME 
$885,512
Company detail
CEO: Kimberly L. Blackwell
Region: US
Website: zentalis.com
Employees: 160
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trials. The company has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC, GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd.

Recent news
loading